VivaGel condom receives regulatory approval in Canada
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- New DEP drug delivery program initiated with AstraZeneca
- Starpharma signs license for a VivaGel condom in China
- Appendix 4C - Quarterly Cashflow Reoprt
- Starpharmas DEP eliminates cabazitaxel neutropenia
- VivaGel active against Zika virus
Later from Starpharma
- Enrolment complete for Phase 3 VivaGel BV-R program
- Additional Priostar Glyphosate Patent Allowed in US
- Starpharma signs license for VivaGel Condom in Iran
- Starpharma receives $3.5M R&D tax incentive refund
- VivaGel BV granted QIDP and Fast Track designation by US FDA
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma